

Ki-67 (MIB-1) Immunostain, Technical Component Only

#### Overview

#### **Useful For**

A marker of proliferation in neoplasms

#### **Reflex Tests**

Test Id	Reporting Name	Available Separately	Always Performed
IHTOI	IHC Initial, Tech Only	No	No
IHTOA	IHC Additional, Tech Only	No	No

#### **Testing Algorithm**

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

#### **Method Name**

Immunohistochemistry (IHC)

## **NY State Available**

Yes

# Specimen

# **Specimen Type**

**TECHONLY** 

# **Ordering Guidance**

This test includes only technical performance of the stain (no pathologist interpretation is performed).

For immunostain detection of Ki-67 for primary invasive or metastatic breast specimens with interpretation by digital analysis, order KI67B / Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated.

For immunostain detection of Ki-67 for primary or metastatic gastrointestinal/pancreatic neuroendocrine tumors with interpretation by digital analysis, order KINET / Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated.

For immunostain detection of Ki-67 for primary or metastatic pulmonary carcinoid tumors with interpretation by digital analysis, order KI67P / Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Automated.



Ki-67 (MIB-1) Immunostain, Technical Component Only

For interpretation and diagnosis of submitted pathology specimens with appropriate additional stains and other ancillary testing, order PATHC / Pathology Consultation.

Additional material may be needed if alternative testing is requested. See the specific specimen requirements for any alternative requested testing.

# **Shipping Instructions**

Attach the green "Attention Pathology" address label (T498) and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.

# Specimen Required Specimen Type: Tissue

**Supplies:** Immunostain Technical Only Envelope (T693) **Container/Tube:** Immunostain Technical Only Envelope

**Submit:** 

-Formalin-fixed, paraffin-embedded tissue block

OR

-2 Unstained, positively charged glass slides (25- x 75- x 1-mm) per test ordered; sections 4-microns thick

## **Digital Image Access**

- 1. Information on accessing digital images of immunohistochemical (IHC) stains and the manual requisition form can be accessed through this website: <a href="https://news.mayocliniclabs.com/pathology/digital-imaging/">https://news.mayocliniclabs.com/pathology/digital-imaging/</a>
- 2. Clients ordering stains using a manual requisition form will not have access to digital images.
- 3. Clients wishing to access digital images must place the order for IHC stains electronically. Information regarding digital imaging can be accessed through this website: <a href="https://news.mayocliniclabs.com/pathology/digital-imaging/#section3">https://news.mayocliniclabs.com/pathology/digital-imaging/#section3</a>

#### **Forms**

If not ordering electronically, complete, print, and send a <u>Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains</u>
<u>Request</u> (T763) with the specimen.

## Reject Due To

Wet/frozen	Reject
tissue	
Cytology	
smears	
Nonformalin	
fixed tissue	
Nonparaffin	
embedded	
tissue	
Noncharged	
slides	
ProbeOn slides	
Snowcoat	



Ki-67 (MIB-1) Immunostain, Technical Component Only

slides	
Silucs	

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
TECHONLY	Ambient (preferred)		
	Refrigerated		

# **Clinical & Interpretive**

#### **Clinical Information**

Ki-67 (antibody clone MIB-1) is a nuclear protein playing a pivotal role in maintaining cell proliferation. Ki-67 is present in all non-G0 phases of the cell cycle. Beginning in the mid-G1 phase, the level increases through the S and G2 phases to reach a peak in M phase. In the end of M phase, it is rapidly catabolized. Ki-67 has been employed as a marker of proliferation and, hence, prognosis in neoplasms of many types, such as malignant lymphomas, prostatic and breast adenocarcinomas, astrocytic neoplasms, and soft tissue neoplasms.

#### Interpretation

This test does not include pathologist interpretation, only technical performance of the stain.

The positive and negative controls are verified as showing appropriate immunoreactivity.

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

#### **Cautions**

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.

The charge of glass slides can be affected by environmental factors and subsequently may alter slide staining. Sending unsuitable glass slides can result in inconsistent staining due to poor slide surface chemistry.

Best practices for storage of positively charged slides:

- -Minimize time slides are stored after being unpackaged
- -Limit exposure to high humidity and heat
- -Minimize exposure to plastics

#### **Clinical Reference**

- 1. Yerushalmi R, Woods R, Ravdin PM et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet. 2010;11(2):174-183
- 2. Leonardo E, Volante M, Barbareschi M, et al. Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol. 2007;15(2):220-223
- 3. Potemski P, Pluciennik E, Bednarek AK, et al. Ki-67 expression in operable breast cancer: a comparative study of



Ki-67 (MIB-1) Immunostain, Technical Component Only

immunostaining and a real-time RT-PCR assay. Pathol Res Pract. 2006;202(7):491-495

- 4. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res. 2004;10(12 Pt 1):4118-4124
- 5. Trihia H, Murray S, Price K, et al. Ki-67 expression in breast carcinoma-its association with grading systems, Clinical parameters, and other prognostic factors-a surrogate marker? Cancer. 2003;97(5):1321-1331
- 6. Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289-298. doi:10.1007/978-1-4939-8935-5\_25

#### **Performance**

## **Method Description**

Immunohistochemistry on sections of paraffin-embedded tissue. (Unpublished Mayo method)

#### PDF Report

No

## Day(s) Performed

Monday through Friday

#### Report Available

1 to 3 days

#### **Specimen Retention Time**

Until staining is complete

#### **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

#### **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

#### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

#### **CPT Code Information**



Ki-67 (MIB-1) Immunostain, Technical Component Only

Bill only; no result

88342-Primary 88341-If additional IHC

# **LOINC®** Information

70793

Test ID	Test Order Name	Order LOINC® Value
KI67	Ki-67 (MIB-1) IHC, Tech Only	Order only;no result
Result ID	Test Result Name	Result LOINC® Value

Ki-67 (MIB-1) IHC, Tech Only